Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aspartic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.71 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.46 |
| ▸ | GRIK2 | Q13002 | 3/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.46 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.44 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.44 |
| ▸ | GRM8 | O00222 | 1/20 | 0.44 |
| ▸ | GRM6 | O15303 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GSR | P00390 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | GRM5 | P41594 | 1/20 | 0.44 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.44 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.44 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.44 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aspartic Acid SCHEMBL850435 | 1.00 | SMN1; SMN2 (0.71) | SMN1; SMN2GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL11065185 | 0.87 | GRIK1 (0.56) | SMN1; SMN2GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL3230 | 0.87 | — | — | |
| Aspartic Acid SCHEMBL31673507 | 0.87 | — | — | |
| Aspartic Acid SCHEMBL996424 | 0.87 | GRIK1 (0.56) | SMN1; SMN2GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL3231 | 0.87 | — | — | |
| Aspartic Acid SCHEMBL11065189 | 0.87 | GRIK1 (0.56) | SMN1; SMN2GRIK1GRIK2GRM1GRM2 | |
| D-Aspartate SCHEMBL145539 | 0.87 | — | — | |
| Aspartic Acid SCHEMBL1526976 | 0.87 | GRIK1 (0.56) | SMN1; SMN2GRIK1GRIK2GRM1GRM2 | |
| Aspartic Acid SCHEMBL31673497 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200054664-A1 | METABOLIC SUPPLEMENT FORMULATION AND METHODS OF USE FOR TREATING DEPRESSION AND ANXIETY | HAWKINS GERMAINE BERNARD (US) | 2020-02-20 | — | — | US | claimed |
| CN-103917651-A | Eukaryotic organisms and methods for producing 1,3-butanediol | GENOMATICA INC | 2014-07-09 | — | — | CN | claimed |
| WO-2024086581-A2 | METHODS FOR DETERMINING THE NATURAL TIME COURSE OF IMMUNE RESPONSE AND METHODS AND COMPOSITIONS FOR MODIFYING INTRACELLULAR PH FOR DISEASE CONTROL | THERAZWIMM CORPORATION (US) | 2024-04-25 | — | — | WO | disclosed |
| US-20240124936-A1 | PROTEIN AND METABOLITE BLOOD BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME | CARDIOMIX S R L (IT) | 2024-04-18 | — | — | US | disclosed |
| CN-115768629-A | Hardcoat compositions and composite films comprising thermoplastic polyurethane | 3M创新有限公司 | 2023-03-07 | — | — | CN | disclosed |
| US-20220315942-A1 | A METHOD FOR THE PRODUCTION OF PLANTS WITH ALTERED PHOTORESPIRATION AND IMPROVED CO2 FIXATION | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2022-10-06 | — | — | US | disclosed |
| EP-4050341-A1 | PROTEIN AND METABOLITE BLOOD BIOMARKERS FOR THE DIAGNOSIS OF BRUGADA SYNDROME | Cardiomix S.r.l. (IT) | 2022-08-31 | — | — | EP | disclosed |
| US-20220211754-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MYOSITIS, COMPRISING ISOLATED MITOCHONDRIA AS ACTIVE INGREDIENT | PAEAN BIOTECHNOLOGY INC. (KR) | 2022-07-07 | — | — | US | disclosed |
| US-20220136059-A1 | Diagnostic Tools and Treatments for Clear Cell Renal Cell Carcinoma | UNIVERSITY OF CINCINNATI (US) | 2022-05-05 | — | — | US | disclosed |
| CN-114051410-A | Pharmaceutical composition for preventing or treating myositis, comprising isolated mitochondria as active ingredient | 白雁生物技术公司 | 2022-02-15 | — | — | CN | disclosed |
| US-20210241846-A1 | MULTICELLULAR METABOLIC MODELS AND METHODS | GENOMATICA INC (US) | 2021-08-05 | — | — | US | disclosed |
| EP-1438580-A1 | COMPOSITIONS AND METHODS FOR MODELING SACCHAROMYCES CEREVISIAE METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2004-07-21 | — | — | EP | disclosed |
| WO-2003036296-A9 | COMPOSITIONS AND METHODS FOR MODELING SACCHAROMYCES CEREVISIAE METABOLISM | UNIV CALIFORNIA (US) | 2004-05-13 | — | — | WO | disclosed |
| EP-1162980-B1 | PYRIDOXINE COMPOUNDS IN THE TREATMENT OF CARDIOVASCULAR PATHOLOGIES | MEDICURE INC (CA) | 2004-02-18 | — | — | EP | disclosed |
| WO-2003082214-A2 | HUMAN METABOLIC MODELS AND METHODS | GENOMATICA, INC. (US) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003036296-A1 | COMPOSITIONS AND METHODS FOR MODELING SACCHAROMYCES CEREVISIAE METABOLISM | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-05-01 | — | — | WO | disclosed |
| EP-1162980-A2 | USE OF PYRIDOXINE COMPOUNDS FOR THE TREATMENT OF CARDIOVASCULAR AND RELATED PATHOLOGIES | Medicure Inc. (CA) | 2001-12-19 | — | — | EP | disclosed |
| WO-2000057863-A2 | USE OF PYRIDOXINE COMPOUNDS FOR TREATMENT OF CARDIOVASCULAR AND RELATED PATHOLOGIES | MEDICURE INC. (US) | 2000-10-05 | — | — | WO | disclosed |
| US-6043259-A | TREATING HYPERTROPHY, CONGESTIVE HEART FAILURE, ISCHEMIA, REPERFUSION INJURY, OR ARRHYTHMIA IN A MAMMAL SUFFERING THEREFROM BY ADMINISTERING TO SAID MAMMAL PYRIDOXINE, PYRIDOXAL-5'-PHOSPHATE, PYRIDOXAL, AND PYRIDOXAMINE | MEDICURE INC. (CA) | 2000-03-28 | — | — | US | disclosed |
| WO-1996033953-A1 | STAIN CORROSION AND SCALE INHIBITORS | ALBRIGHT & WILSON UK LIMITED (GB) | 1996-10-31 | — | — | WO | disclosed |